Patents Assigned to REMEGEN, LTD.
  • ANTI-MESOTHELIN ANTIBODY AND ANTIBODY DRUG CONJUGATE THEREOF
    Publication number: 20220056147
    Abstract: The present invention discloses an antibody drug conjugate that targets MSLN. The present invention also disclosed a method of making the antibody drug conjugate (ADC). The present invention further discloses a novel MSLN antibody or a functional fragment thereof comprising engineered heavy and light chains.
    Type: Application
    Filed: May 15, 2019
    Publication date: February 24, 2022
    Applicant: Remegen, Ltd.
    Inventors: Jianmin Fang, Changjiang Huang, Jing Jiang, Hui Ye, Shenjun Li, Qiaoyu Xu, Wenting Luo, Mingxue Wang
  • Anti-HER2 antibody and conjugate thereof
    Patent number: 10087260
    Abstract: Disclosed are an anti-HER2 antibody and conjugate of the anti-HER2 antibody and small molecule medicine. Also disclosed are uses of the antibody and conjugate thereof in preparing medicine for treating tumor.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: October 2, 2018
    Assignee: REMEGEN, LTD.
    Inventors: Jianmin Fang, Changjiang Huang, Jing Jiang, Xuejing Yao, Hongwen Li, Qiaoyu Xu, Zhuanglin Li
  • FGFR-FC fusion proteins and the use thereof
    Patent number: 9957313
    Abstract: The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: May 1, 2018
    Assignee: REMEGEN, LTD.
    Inventors: Jianmin Fang, Dong Li
  • ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF
    Publication number: 20160304621
    Abstract: Disclosed are an anti-HER2 antibody and conjugate of the anti-HER2 antibody and small molecule medicine. Also disclosed are uses of the antibody and conjugate thereof in preparing medicine for treating tumor.
    Type: Application
    Filed: November 18, 2014
    Publication date: October 20, 2016
    Applicant: REMEGEN, LTD.
    Inventors: Jianmin FANG, Changjiang HUANG, Jing JIANG, Xuejing YAO, Hongwen LI, Qiaoyu XU
  • FGFR-Fc fusion proteins and the use thereof
    Patent number: 9273137
    Abstract: The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related diseases. Particularly, the present invention relates to FGFR-Fc fusion proteins and the use thereof in the treatment of angiogenesis regulation-related diseases. More particularly, the present invention relates to isolated soluble FGFR-Fc fusion proteins and their applications in manufacture of the medicament for the treatment of angiogenesis regulation-related diseases.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 1, 2016
    Assignee: REMEGEN, LTD.
    Inventors: Jianmin Fang, Dong Li